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Strengths and limitations of this study
 ► This is the first study to use an Src/c- Abl inhibitor, 
bosutinib, for patients with amyotrophic lateral scle-
rosis (ALS), and is considered to be the first step in 
the development of a molecular- targeted therapy for 
ALS.
 ► This study presents a novel type of protocol design 
by combining the safety study of oncology and the 
efficacy study of neurology.
 ► Limitations are the open- label and single- arm de-
signs for safety and tolerability.
AbStrACt
Introduction Amyotrophic lateral sclerosis (ALS) is 
a progressive and severe neurodegenerative disease 
caused by motor neuron death. There have as yet been no 
fundamental curative medicines, and the development of a 
medicine for ALS is urgently required. Induced pluripotent 
stem cell (iPSC)- based drug repurposing identified an 
Src/c- Abl inhibitor, bosutinib, as a candidate molecular 
targeted therapy for ALS. The objectives of this study are 
to evaluate the safety and tolerability of bosutinib for the 
treatment of patients with ALS and to explore the efficacy 
of bosutinib on ALS. This study is the first clinical trial of 
administered bosutinib for patients with ALS.
Methods and analysis An open- label, multicentre phase 
I dose escalation study has been designed. The study 
consists of a 12- week observation period, a 1- week 
transitional period, a 12- week study treatment period 
and a 4- week follow- up period. After completion of the 
transitional period, subjects whose total ALS Functional 
Rating Scale- Revised (ALSFRS- R) score decreased by 
1–3 points during the 12- week observation period receive 
bosutinib for 12 weeks. Three to six patients with ALS 
are enrolled in each of the four bosutinib dose levels 
(100, 200, 300 or 400 mg/day) to evaluate the safety and 
tolerability under a 3+3 dose escalation study design. Dose 
escalation and maximum tolerated dose are determined by 
the safety assessment committee comprising oncologists/
haematologists and neurologists based on the incidence 
of dose- limiting toxicity in the first 4 weeks of the 
treatment at each dose level. A recommended phase II 
dose is determined by the safety assessment committee 
on completion of the 12- week study treatment in all 
subjects at all dose levels. The efficacy of bosutinib is 
also evaluated exploratorily using ALS clinical scores and 
biomarkers.
Ethics and dissemination This study received full 
ethical approval from the institutional review board of 
each participating site. The findings of the study will be 
disseminated in peer- reviewed journals and at scientific 
conferences.
trial registration number UMIN000036295; Pre- results, 
JMA- IIA00419; Pre- results.
IntroduCtIon
Amyotrophic lateral sclerosis (ALS) is an 
intractable neurodegenerative disease caused 
by the death of motor neurons resulting in 
progressive skeletal muscle weakness. The 
worldwide incidence of ALS is approximately 
2 per 100 000 persons per year.1 About 10% of 
patients with ALS have familial inheritance, 
and in Japan,2 around 30% of those patients 
have SOD1 gene mutation.3 Although the 
disease mechanism of ALS is still unknown, 
motor neuron death and accumulation of 
misfolded proteins are essential patholog-
ical characteristics of the disease. In the 
late stage of the disease, patients lose their 
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box 1 Criteria for severity of amyotrophic lateral 
sclerosis (ALS) (Ministry of Health and Welfare Study Group 
on neurodegenerative diseases as Specified diseases, 
1998)
 ► Grade 1: Able to work or perform housework; movement distur-
bance of one limb or dysarthria caused by bulbar palsy.
 ► Grade 2: Independent living but inconveniences in daily life; move-
ment disorders of one or two limbs, trunk, tongue, face, palate, 
larynx.
 ► Grade 3: Requiring assistance for eating, excretion or ambulation; 
three or more muscle weaknesses in limbs, trunk, tongue, face, pal-
ate and larynx.
 ► Grade 4: Need assistance in everyday life; presence of respiratory 
insufficiency, difficulty in coughing out sputum or dysphagia.
 ► Grade 5: Bedridden and full life support equipment required.
(Source: FDA edaravone medical review /MCI186-19- Protocol, Section 16.1.1, 
p250/267)
ALSFRS- R, ALS Functional Rating Scale- Revised.
respiratory failure. The survival period is within 3–5 years 
after onset if a mechanical ventilator is not adopted.4 To 
date, riluzole5 and edaravone6 have been approved for 
ALS treatment, although there are no fundamental cura-
tive medicines.
We previously identified bosutinib, an Src/c- Abl inhib-
itor, as resulting in an increase in the survival rate of ALS 
motor neurons derived from familial ALS with SOD1 muta-
tion and from sporadic ALS patients’ induced pluripo-
tent stem cells (iPSCs). Bosutinib improved the impaired 
autophagy, reduced the accumulation of misfolded 
proteins and attenuated the energy shortage of ALS 
patient motor neurons.7 Furthermore, treatment with 
bosutinib attenuated the ALS- related phenotypes of ALS 
model mice.7 8 Penetration of the blood–brain barrier was 
confirmed by a previous report.9 Based on these findings, 
we hypothesised that bosutinib, as a molecular targeted 
therapy, would attenuate the progression of muscle weak-
ness and elongate the survival period of patients with 
ALS according to its pathomechanism- dependent effects, 
and thus we designed the clinical trial of bosutinib for 
patients with ALS.
Bosutinib is a selective inhibitor of Src/c- Abl tyrosine 
kinase, approved for the treatment of chronic myelog-
enous leukaemia (CML). In September 2012, the US 
Food and Drug Administration (FDA) approved bosu-
tinib for the treatment of CML, chronic, accelerated or 
blast phase Philadelphia chromosome- positive CML, for 
those who are resistant to or who cannot tolerate other 
therapies including imatinib. Then, FDA granted accel-
erated approval of bosutinib for the treatment of patients 
with newly diagnosed CML in December 2017. Although 
known frequent adverse effects include diarrhoea, 
thrombocytopenia and liver transaminase elevations,10 
from the results of past clinical trials with patients with 
CML, it became clear that the safety of bosutinib can be 
managed. However, because the disease- related physical 
conditions of patients with ALS are different from those 
of patients with CML, evaluation of the safety and tolera-
bility of bosutinib in patients with ALS was planned to be 
conducted in the present study. Also, evaluation of the 
efficacy of bosutinib in patients with ALS using ALS Func-
tional Rating Scale- Revised (ALSFRS- R)11 and biomarkers 
was designed to be conducted in an exploratory manner.
MEtHodS
Study design
This study is an investigator- initiated, open- label, multi-
centre, phase I dose escalation study to evaluate the safety 
and tolerability of bosutinib for determination of the 
maximum tolerated dose (MTD) and a recommended 
phase II dose (RP2D) in patients with ALS. Efficacy is also 
evaluated exploratorily.
The following patients will be included in this study.
 ► Patients with sporadic ALS diagnosed with isolated 
definite, probable or probable- laboratory supported 
ALS as determined by the Updated Awaji Criteria,12 or 
patients diagnosed with ALS with progressive muscle 
weakness and a superoxide dismutase 1 (SOD1) mutation 
(which has already been reported).
 ► Patients with Grade 1 or 2 ALS according to ALS 
severity classification as determined by the Japanese 
Ministry of Health, Labour and Welfare (MHLW) 
Specific Disease Research Group in Japan (box 1); 
patients with Grade 3 ALS with a SOD1 mutation are 
allowed to be enrolled.
 ► Patients with ALS within 2 years after onset at the 
time of primary enrolment (patients with ALS with 
an SOD1 mutation within 5 years after the onset are 
allowed to be enrolled).
 ► Patients with total ALSFRS- R score reduced by 1–3 
points during the observation period.
Detailed eligibility criteria are presented in box 2. In 
order to avoid undesirable carry- over effects caused by 
previous medications, patients taking edaravone were 
excluded and riluzole use during the study treatment 
period was prohibited. To ensure patient safety and to 
evaluate the safety of bosutinib appropriately, bulbar type 
ALS was excluded.
The study consists of a 12- week observation period, a 
1- week transitional period, a 12- week study treatment 
period and a 4- week follow- up period (figure 1). Subjects 
who have been receiving riluzole are allowed to continue 
to take riluzole during the 12- week observation period 
(with the dosage remaining unchanged), but they must 
stop taking riluzole from the beginning of the 1- week 
transitional period. After completion of the transitional 
period, subjects whose total ALSFRS- R score decreased 
by 1–3 points during the 12- week observation period will 
receive bosutinib for 12 weeks to evaluate its safety and 
tolerability in patients with ALS. All ALS drugs including 
riluzole will be prohibited during the bosutinib treat-
ment period. In this study, three to six patients with ALS 
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box 2 Eligibility criteria
Inclusion criteria:
1. Evidence of a personally signed and dated informed consent docu-
ment indicating that the patient has been informed of all pertinent 
aspects of the study. To be additionally signed by a delegate signer 
if the subject is unable to handwrite.
2. Patients aged ≥20 years and <80 years at the time of informed 
consent.
3. Patients with positive already- reported SOD1 gene mutation and 
progressive muscle weakness; patients with sporadic ALS who are 
categorised as either ‘Definite ALS’ or ‘Probable ALS’ or ‘Probable- 
laboratory supported ALS’ in the Updated Awaji Criteria for the di-
agnosis of ALS.
4. Patients at Grade 1 or 2 in the Japan ALS Severity Scale of the 
grant- in- aid programme for chronic diseases from the Japanese 
Ministry of Health, Labour and Welfare; patients with positive SOD1 
mutation of Grade 1, 2 or 3.
5. Patients with ALS that occurred within 2 years at the time of the 
first registration; patients with positive SOD1 mutation within 5 
years after disease onset
6. Patients who can visit hospitals regularly as outpatients.
7. Patients with change in total ALSFRS- R score during the observa-
tion period from −1 to −3 points.
8. Urine pregnancy test (for female of childbearing potential) negative 
at screening.
Female patients of non- childbearing potential must meet at least 
one of the following criteria:
a. Achieved postmenopausal status defined as follows: cessation 
of regular menses for at least 12 consecutive months with no 
alternative pathological or physiological cause; status may be 
confirmed with a serum follicle- stimulating hormone level con-
firming the postmenopausal state.
b. Have undergone a documented hysterectomy and/or bilateral 
oophorectomy.
c. Have medically confirmed ovarian failure.
All other female patients (including female patients with tubal 
ligations) are considered to be of childbearing potential.
Male and female patients of childbearing potential must agree to 
use one highly effective method of contraception as outlined in 
this protocol, throughout the study and for at least 28 days after 
the last dose of investigational product.
9. Patients with appropriate renal function as defined as follows at the 
time of the first and second registrations.
a. Serum creatinine ≤1.5 × upper limit of normal (ULN) or estimated 
creatinine clearance ≥60 mL/min as calculated using the stand-
ard method for the institution.
10. Patients with appropriate hepatic function as defined as follows at 
the time of the first and second registrations.
a. Total serum bilirubin ≤1.5 × ULN unless the patient has docu-
mented Gilbert syndrome.
b. AST and ALT≤2.5 × ULN.
11. Able to take tablets orally.
12. Patients whose acute effect of previous treatment has recovered to 
the baseline or CTCAE v.4.03≤Grade 1 at the time of the first and 
second registrations.
13. Willing and able to comply with scheduled visits, treatment plan, 
laboratory tests and other study procedures.
Exclusion criteria:
1. Patients with tracheostomy.
Continued
box 2 Continued
2. Patients who have used non- invasive ventilation due to ALS 
symptoms.
3. Patients whose % Forced vital capacity (FVC) is less than 70% at 
the time of first and second registrations.
4. Patients who have nerve conduction study findings of demyelina-
tion such as conduction block.
5. Patients who are taking edaravone; patients who started riluzole 
or edaravone after start of the observation period; patients who 
changed the dosage of riluzole after start of the observation period.
6. Patients with bulbar type ALS with dysphagia and dysarthria.
7. Patients with cognitive impairment.
8. Pregnant female patients; breastfeeding female patients; fertile 
male and female patients of childbearing potential who are unwill-
ing or unable to use one highly effective method of contraception 
as outlined in this protocol for the duration of the study and for at 
least 28 days after the last dose of the investigational product.
9. History of clinically significant or uncontrolled cardiac disease 
including:
 – History of, or active, congestive heart failure.
 – Uncontrolled angina or hypertension within 3 months prior to 
registration.
 – Myocardial infarction within 12 months prior to registration.
 – Clinically significant ventricular arrhythmia (such as ventricular 
tachycardia, ventricular fibrillation or Torsades de pointes).
 – Diagnosed or suspected congenital or acquired prolonged QT in-
terval history or prolonged QTc (QTcF should not exceed 500 ms).
 – Unexplained syncope.
10. Uncontrolled hypomagnesaemia or uncorrected hypokalaemia due 
to potential effects on the QT interval.
11. Patient who is taking the following medicines during study drugs 
administration.
a. Combination of warfarin anticoagulation or related oral antico-
agulation. Combination of therapeutic anticoagulant therapy with 
low molecular weight heparin is acceptable.
b. Src or c- Abl inhibitors.
c. Other treatments for cancer.
d. Drugs known to prolong the QT interval or predispose to Torsades 
de Pointes.
e. Current or anticipated use of a strong or moderate CYP3A inhib-
itor and inducer.
f. Drugs affecting gastric pH such as proton pump inhibitors (eg, 
lansoprazole).
12. History of malignancy within 5 years prior to registration with the 
exception of basal cell carcinoma or cervical carcinoma in situ or 
stage 1 or 2 cancer that is considered adequately treated and cur-
rently in complete remission for at least 12 months.
13. Patients who were enrolled in other clinical study within 12 weeks 
before the first registration or are expected to be enrolled in other 
clinical study using a study drug during this study.
14. Known prior or suspected severe hypersensitivity to study drugs or 
any component in their formulations.
15. Patients with active, uncontrolled bacterial, fungal or viral infection, 
including hepatitis B virus, hepatitis C virus, known HIV or AIDS- 
related illness.
16. Recent or ongoing clinically significant GI disorder (eg, Crohn’s dis-
ease, ulcerative colitis, or prior total or partial gastrectomy).
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box 2 Continued
18. Major surgery or radiotherapy within 14 days prior to registration at 
the time of the first registration.
19. Patient who fulfils the conditions:
a. Neutrophil count (ANC)<1500/mm3 or white cell count <3000/
mm3 at the time of the first and second registrations.
b. Haemoglobin<9.0 g/dL at the time of the first and second 
registrations.
c. Platelet count <1 00 000/L at the time of the first and second 
registrations.
20. Other acute or chronic medical or psychiatric condition including 
recent (within the past year) or active suicidal ideation or behaviour 
or laboratory abnormality that may increase the risk associated 
with study participation or investigational product administration 
or may interfere with the interpretation of study results and, in the 
judgement of the investigator, would make the participant inappro-
priate for entry into this study.
21. Investigation site staff members directly involved in the conduct of 
the study and their family members, site staff members otherwise 
supervised by the investigator (subinvestigator), including their 
family members.
ALS, amyotrophic lateral sclerosis; ALSFRS- R, ALS Functional Rating Scale- 
Revised;
GI, gastrointestinal.
Figure 1 Study schedule of the iDReAM (Induced 
pluripotent stem cell–based Drug Repurposing for 
Amyotrophic lateral sclerosis Medicine) study.
Figure 2 3+3 dose escalation study design in the iDReAM 
(Induced pluripotent stem cell–based Drug Repurposing for 
Amyotrophic lateral sclerosis Medicine) study. DLT, dose- 
limiting toxicity.
box 3 definition of dLt
 ► Grade 4 neutropenia (<500/mm3) persisting for >7 day duration or 
Grade 4 white cell count decrease for >7 day duration (<1000/mm3).
 ► Febrile neutropenia (ANC<1000/mm3 and fever ≥38.5°C).
 ► Grade 4 thrombocytopenia >48 hour duration or with bleeding re-
quiring platelet transfusion.
 ► Any Grade 3 or 4 clinically evident non- haematological toxicity
 – except for ≥Grade 3 nausea, vomiting or diarrhoea unless subject 
is on optimal medical therapy, or
 – electrolyte abnormality requiring hospitalisation, or is 
life- threatening.
 ► ≥66% of bosutinib doses that cannot be completed due to an ad-
verse event related to the investigational drug (during the first 4 
weeks of treatment and the entire 12 weeks of treatment).
 ► An event otherwise determined as a DLT by principal (sub) investi-
gator and the safety assessment committee.
 ► Any clinically significant ≥Grade 2 toxicity that requires >14 days to 
resolve (to ≤Grade 1 despite optimal medical therapy).
Remarks: Respiratory failure is a very important clinical event for amyotrophic 
lateral sclerosis (ALS). Thus, dyspnoea, hypoxia, pneumonitis, pulmonary 
oedema and pulmonary fibrosis according to CTCAE V.4.03 will be considered 
as ‘clinically relevant ≥Grade 2 adverse events.’
Toxicity of bosutinib in patients with ALS is not known.Dose- limiting toxicity 
(DLT) criteria may be modified or added if it is considered necessary to include 
additional DLT criteria deemed appropriate for patients with ALS based on 
information accumulated from this study.
(100 mg/day (dose level 1), 200 mg/day (dose level 2), 
300 mg/day (dose level 3) or 400 mg/day (dose level 
4)) to evaluate the safety and tolerability of the investi-
gational drug (bosutinib) under a 3+3 dose escalation 
study design13 (figure 2). The dose will be escalated by 
one dose level at a time; no skipping will be allowed. 
Dose escalation and MTD will be determined based on 
assessment by the safety assessment committee consisting 
of oncologists and haematologists, as well as a neurolog-
ical expert who is also an ALS expert, as measured by 
the incidence of dose- limiting toxicity (DLT) for 4 weeks 
after initiating each dose level. The definition of DLT is 
shown in box 3. RP2D is the dosage selected according 
to the results of a phase I study for uses in future studies 
and will be projected as a recommended clinical dose 
for patients with ALS. Thus, in order to confirm its suit-
ability for long- term clinical administration, RP2D will be 
selected comprehensively based on the evaluation of all 
safety data obtained (including DLT, dose intensity and 
other relevant data throughout the treatment period), as 
well as pharmacological data, exploratory endpoints and 
other relevant data.
The target sample size of this clinical trial is 12–24 
subjects. The number of subjects at each dose level of this 
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outcomes
The primary endpoint is DLT during the first 4 weeks of 
treatment with bosutinib, and during the study treatment 
period (12 weeks). Adverse events, abnormal laboratory 
test results, vital signs (blood pressure, pulse rate, body 
temperature), ECG and chest X- ray findings are evaluated 
as secondary endpoints. Adverse events are graded based 
on the National Cancer Institute (NCI) Common Termi-
nology Criteria for Adverse Events (CTCAE) V.4.03. Phar-
macokinetic assessments will be conducted for subjects 
who have serious adverse events. Changes in ALS clinical 
score including total ALSFRS- R score and in the grade of 
the Japan ALS severity classification, and changes from 
the baseline of %FVC and grip power are evaluated as 
exploratory endpoints. Changes in blood neurofilament 
L (NF- L) and phosphorylated neurofilament H (pNF- H) 
during the observation period and the study treatment 
period are also evaluated as exploratory endpoints.
data analysis and statistical method
The frequency of DLT during the study treatment period 
will be analysed for each dose level. The frequencies of 
adverse events during the study treatment period are 
analysed for each dose group. Onset timing, severity and 
the relationship of the study drug to adverse events are 
summarised. The respective correlations of changes in 
total ALSFRS- R score versus blood NF- L and blood pNF- H 
will be assessed.
Patient and public involvement
Patients and the public were not involved in the design 
of this study.
registration
This study has been planning since March 2019 to March 
2021, and participating four sites in Japan.
dISCuSSIon
This study evaluates the safety and tolerability of bosu-
tinib for the molecularly targeted treatment of patients 
with ALS as well as explores the efficacy of bosutinib on 
ALS. The potential efficacy of bosutinib for patients with 
ALS has already been identified by an approach applying 
iPSC- based drug repurposing.7 We previously developed 
a phenotypic screen system to evaluate compounds with 
a readout of motor neuron survival using ALS patient- 
iPSCs with SOD1 mutations.7 Application of the screen 
revealed that bosutinib increased the survival rate of ALS 
motor neurons. This drug was also effective for sporadic 
ALS patient- iPSC models. Thus, we designed the clinical 
trial for ALS patients with SOD1 mutation and for patients 
with sporadic ALS, with the expectation that bosutinib will 
become a candidate molecularly targeted drug for ALS.
Bosutinib is a therapeutic agent used for the treat-
ment of patients with CML, and the accumulated data of 
previous clinical trials presenting the safety of bosutinib 
can also be managed in patients with CML. However, 
evaluation of the safety and tolerability of bosutinib in 
patients with ALS is required in order to support the 
development of bosutinib for the treatment of ALS. This 
clinical trial was designed as a ‘triple 3 design’ by a combi-
nation of the safety study, the 3+3 dose escalation study 
design of oncology and the efficacy study, with a 3- month 
observation period for uniform subject inclusion, of 
neurology.
Safety information has been accumulated from clin-
ical studies of bosutinib in patients with CML. Known 
frequent adverse effects of bosutinib include diarrhoea 
(70%), thrombocytopenia (35%) and liver enzyme 
abnormalities (alanine aminotransferase increase of 31%, 
aspartate aminotransferase increase of 23%) according 
to the Bosutinib Trial in First- Line Chronic Myelogenous 
Leukemia Treatment (BFORE) trial, which demonstrated 
the efficacy of bosutinib as first- line treatment in adult 
patients with newly diagnosed chronic- phase CML.10 
While diarrhoea is the most commonly reported adverse 
event, it is generally manageable by dietary advice to 
avoid dairy products, high fat content and spicy food 
before anti- diarrhoeal agents.10 Patients with haemato-
logical adverse events or liver transaminase elevations are 
managed by dose interruption or reduction.10 The occur-
rence and management of adverse events in patients with 
ALS seem to be comparable to those with CML. While 
referring to the accumulated clinical data of CML, this 
study was designed to evaluate any unacceptable adverse 
events that specifically occur in patients with ALS, as well 
as the treatment tolerability in patients with ALS. Given 
that a 4- week DLT evaluation period was included in 
the phase I/II study to determine MTD in patients with 
CML (NCT00811070), a 4- week DLT evaluation period is 
included in this study to determine MTD with bosutinib 
in patients with ALS. In addition to MTD, this study deter-
mines RP2D considered optimal for patients with ALS. 
After discussion with the regulatory authority referencing 
the clinical data of CML, 12 weeks of the study treatment 
period is considered necessary to determine RP2D in the 
current study. Regarding the dose, a 400 mg dose of bosu-
tinib has been approved by FDA as a first- line treatment 
for CML. For the non- oncology study of bosutinib, a phase 
2 study has been conducted in patients with autosomal 
dominant polycystic kidney disease, in which bosutinib at 
starting doses of 200 and 400 mg/day was administered.14 
Thus, up to 400 mg of bosutinib dose was selected for 
evaluation of the safety and tolerability for patients with 
ALS in this study. Regarding the drug interaction, CYP3A 
inhibitors/inducers are prohibited because bosutinib is 
primarily metabolised by CYP3A. Drugs affecting gastric 
pH are also prohibited because blood concentration of 
bosutinib may be decreased, resulting in reduced efficacy.
Patients with ALS eventually develop degeneration of 
both upper and lower motor neurons, but their symp-
toms and disease processes vary.15 In the early stage of 
the disease, only upper or lower motor neuron signs 
may manifest themselves. Some patients also continue to 
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long periods of time. Especially, ALS patients with an 
SOD1 mutation often do not meet typical ALS diagnostic 
criteria because they lack upper motor neuron signs, and 
they sometimes present a different clinical prognosis from 
sporadic ALS,16 showing slow progression in some cases. 
Thus, inclusion criteria contained special provisions for 
ALS patients with an SOD1 mutation.
The variety of clinical symptoms and disease progres-
sion speed among patients is one of the reasons that 
cause difficulty for clinical trial evaluation. In the current 
study, an observation period of 12 weeks was established 
to enable the evaluation of ALS patients with uniform 
progression speed, the same as in previous clinical trials 
with edaravone, which was approved for ALS to cause a 
delay in motor function decline.6 To explore the efficacy 
of bosutinib, a change in ALS clinical score such as the 
ALSFRS- R score, the grade in Japan ALS severity classi-
fication, a change from baseline of %FVC and a change 
in grip power are all evaluated as exploratory endpoints. 
In addition, blood NF- L levels and pNF- H levels, which 
have been reported to be increased in blood and cerebro-
spinal fluid of patients with ALS,17–19 are also evaluated 
as an indicator of the effectiveness of bosutinib. These 
biomarkers might indicate the degree of motor neuron 
death, and its alteration might reflect the effect of bosu-
tinib treatment.
This study is the first to use an Src/c- Abl inhibitor, bosu-
tinib, for patients with ALS, and it presents a novel type of 
protocol design by combining a safety study for oncology 
and an efficacy study for neurology. This is a phase I study 
for the safety and tolerability evaluation, and the number 
of subjects was limited. Therefore, it will be necessary 
to conduct further safety and efficacy evaluations in the 
following phases. This study is considered to be the first 
step in the development of a molecularly targeted drug 
for ALS therapy.
Ethics and dissemination
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